Amgen announces results from several new exploratory analyses of treatment with Prolia®
Amgen and UCB announced results from several exploratory analyses of the Phase 2 study evaluating romosozumab in postmenopausal women with low bone mineral density. Romosozumab is an investigational bone-forming agent that is designed to work by inhibiting the protein sclerostin. September 15, 2014